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Abstract
Background: TAR DNA-binding protein 43 (TDP-43) is a nuclear protein, but it is redistributed in the neuronal
cytoplasm in both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Because small
transgenic animal models often lack cytoplasmic TDP-43, how the cytoplasmic accumulation of TDP-43 contributes
to these diseases remains unclear. The current study is aimed at studying the mechanism of cytoplasmic pathology
of TDP-43.
Results: We established transgenic pigs expressing mutant TDP-43 (M337V). This pig model shows severe phenotypes
and early death. We found that transgenic TDP-43 is also distributed in the cytoplasm of neuronal cells in the spinal
cord and brain. Transgenic TDP-43 interacts with PSF, an RNA splicing factor that associates with NeuN to regulate
neuronal RNA splicing. The interaction of TDP-43, PSF and NeuN causes PSF and NeuN mislocalize into the neuronal
cytoplasm in transgenic pigs. Consistently, abnormal PSF-related neuronal RNA splicing is seen in TDP-43 transgenic
pigs. The cytoplasmic localization of PSF and NeuN as well as abnormal PSF-related neuronal RNA splicing was also
found in ALS patient brains.
Conclusion: Our findings from a large mammalian model suggest that cytoplasmic mutant TDP-43 could reduce the
nuclear function of RNA splicing factors, contributing to neuropathology.
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Background
TAR DNA-binding protein 43 (TDP-43) is a multifunc-
tional, nuclear protein that binds RNA to regulate RNA
processing, including alternative splicing, miRNA pro-
duction, and mRNA trafficking and stabilization [1–6].
TDP-43 has two conserved RNA recognition motifs and
a C-terminal glycine-rich domain that mediates interac-
tions with other heterogeneous nuclear ribonucleopro-
tein (hnRNP) family members [7, 8]. Mutations in the
C-terminal domain of TDP-43 are associated with both
amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD) [9–11]. ALS is characterized
by progressive degeneration of large motor neurons in
the spinal cord and cerebral cortex, and FTLD causes
degeneration of neurons in the frontal and temporal cor-
tices. In both diseases, the key pathological change is
that pathogenic TDP-43 is accumulated in the cytoplasm
and forms cytoplasmic aggregates [12–14]; however, how
cytoplasmic mislocalization of TDP-43 contributes to
pathogenesis remains to be investigated.
To date, a variety of transgenic TDP-43 animal models
have been established and provided us with valuable tools
to uncover gene expression alteration and aberrant RNA
splicing caused by TDP-43 [5, 7, 15]. Although overexpres-
sion of mutant TDP-43 in cultured cells and some rodent
models and deletion of the nuclear localization signal in
TDP-43 can lead to the cytoplasmic distribution of mutant
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TDP-43, many transgenic TDP-43 mouse models fail to
show the cytoplasmic accumulation of mutant TDP-43
[16–24], suggesting that species-dependent differences
may account for differential pathology of TDP-43 in
small animals and human patients. Given that TDP-43
is a multifunctional nuclear protein whose expression is
tightly regulated [25], mutant TDP-43 or altered levels
of normal TDP-43 can cause neuropathology. However,
because most of current animal models lack the cytoplas-
mic accumulation of TDP-43, our ability to investigate how
the cytoplasmic mislocalization of TDP-43 contributes to
the pathogenesis has been limited.
The lack of cytoplasmic mislocalization of TDP-43 in
small animals may be due to unknown species differences
that regulate the subcellular localization of TDP-43. Be-
cause of the greater similarity between pigs and humans,
we have used transgenic pigs to investigate the pathology
caused by mutant polyglutamine proteins and SOD1 and
uncovered unique pathology not seen in small animals
[26, 27]. In the current study, we established transgenic
miniature pigs expressing mutant TDP-43 and found that
transgenic TDP-43 is also distributed in the cytoplasm
of neuronal cells and causes severe phenotypes in pigs.
Moreover, this new animal model demonstrates that
mutant TDP-43 interacts with the RNA splicing factor
PSF (Splicing Factor Proline/Glutamine-Rich) and the
cytoplasmic localization of PSF as well as reducing nuclear
PSF function in RNA splicing. Thus, by establishing a
large mammalian model of TDP-43, we provide fresh
insight into the role of cytoplasmic mislocalization of
mutant TDP-43 in the pathogenesis of ALS and FTLD.
Results
Generation of transgenic pigs expressing mutant TDP-43
There are a number of mutations in human TDP-43,
and transgenic expression of wild type human TDP-43
also causes neuropathology in animal models [22, 28].
Considering that generation of transgenic pigs is much
more time-consuming and costly than small animal
models, we focused on the generation of transgenic
pigs expressing human mutant TDP-43 (M337V), but
not wild type TDP-43, and compared them with non-
transgenic pigs. Using the same somatic cell nuclear
transfer (SCNT) approach for generating transgenic
pig models of Huntington’s disease and ALS [26, 27],
we transfected mutant TDP-43 (M337V) in primary
pig fetal fibroblasts isolated from 35-day-old Tibetan
miniature pig fetus. Mutant TDP-43 is tagged with the
flag epitope at its N-terminus and expressed under the
control of the human ubiquitin promoter that can
drive gene expression ubiquitously, and the transgene
also co-expresses EGFP for identifying transfected
cells that express TDP-43 (Fig. 1a). The transfected
cells expressing TDP-43 were fused to a total of 2270
SCNT embryos, which were transferred into 13 surro-
gates that exhibited natural estrus. Seven surrogates
developed to term and gave birth to 31 healthy Ti-
betan miniature piglets after 120–130 d of gestation.
Of these, 27 piglets were found to be positive for
transgenic TDP-43 via PCR (Fig. 1b), as PCR analysis
of DNA samples obtained from the ear tissues of pig-
lets showed that the live piglets were positive for the
TDP-43 transgene (Fig. 1c).
Newborn transgenic TDP-43 pigs appeared as normal
at birth as non-transgenic pigs. However, they started to
gain less body weight from 3 months after birth com-
pared to non-transgenic pigs (Fig. 2a and b). The extent
of body weight loss appears to be correlated with the ex-
pression levels of TDP-43 in pig ear tissues (Fig. 2c).
Many transgenic TDP-43 pigs die earlier starting at the
age of 4–5 months, and 85 % (21/27) of the TDP-43
transgenic pigs died within one year (Fig. 2d). As a result
of gaining considerable less body weight during develop-
ment, the transgenic TDP-43 pigs often displayed loose
skin characterized by wrinkled and sagging skin on their
bodies (Fig. 2e). We previously established ALS pigs ex-
pressing mutant SOD1, which grew normally without
body weight loss but showed an obvious running defect
on a treadmill [27]. Like these ALS transgenic pigs,
the TDP-43 transgenic pigs also showed progressive
weakness and limb movement defects (Fig. 2f ). How-
ever, following the training for the treadmill test, some
TDP-43 pigs died, which did not allow us to use the
treadmill to obtain quantified data of the limb move-
ment impairment for TDP-43 pigs. Therefore, we used
the surviving TDP-43 pigs, not including those that
died right after treadmill test, to assess the growth, life
span, and motor deficit of TDP-43 pigs. We found that
there was the progressive reduction in the body weight
and that transgenic TDP-43 pigs died earlier than non-
transgenic pigs. The shorter life span and the more severe
motor deficit in TDP-43 pigs than those of our previously
reported transgenic SOD1 pigs [27] suggest that mutant
TDP-43 elicits more toxicity than mutant SOD1 in trans-
genic pigs.
Of the dead TDP-43 pigs, we were able to collect brain
tissues from some animals for western blotting and
immunohistochemical studies. Using anti-TDP-43 (G400,
Cell Signaling), which recognizes endogenous pig TDP-43
and flag-tagged transgenic TDP-43 via western blotting,
we found that the levels of transgenic TDP-43 in the
spinal cord and cerebellar cortex tissues in different trans-
genic pigs are lower than or equivalent to the endogenous
pig TDP-43 (Fig. 3a). Also, transgenic TDP-43 is widely
expressed in different brain regions, including the cerebel-
lum, striatum, and brain stem (Fig. 3b). It is known that
the expression level of TDP-43 is tightly self-regulated
[29]. By measuring the ratios of endogenous pig TDP-43
Wang et al. Molecular Neurodegeneration  (2015) 10:42 Page 2 of 20
to actin in non-transgenic pigs and mutant TDP-43 to
actin in transgenic TDP-43 pig brains, we found that the
expression levels of mutant TDP-43 are not overexpressed
(Fig. 3b). Western blotting also revealed small TDP-43 im-
munoreactive bands (Fig. 3b), which are likely cleaved
transgenic TDP-43 fragments as they were not seen in the
non-TG control pig brain. In the pig brain cortex, we saw
a reduction in the thickness of different layers [(the thick-
ness of layers II-VI (non-TG 1396.9 ± 51.67 μm vs TG
1038.05 ± 36.49 μm (mean ± SE, n = 4)] with a reduced
density of NeuN-positive cells in the TDP-43 transgenic
pig brain (Fig. 3c), which indicates neurodegeneration in
TDP-43 transgenic pig brains.
We know that mutant TDP-43 affects the spinal cord
motor neurons to cause ALS [30, 31], so we examined
the numbers of motor neurons in the ventral horn of
lumbar spinal cords via immunostaining with antibodies
to NeuN and CHAT, which is specifically expressed in
motor neurons. There were fewer NeuN-positive and
CHAT-positive motor neurons (Fig. 4a) in the spinal
cord of TDP-43 transgenic pigs. Counting the numbers
of these neurons showed that motor neurons were de-
creased obviously in the ventral horn of lumbar spinal
cord of transgenic pigs (Fig. 4b). The degeneration of
spinal cord motor neurons causes denervated skeletal
muscle in ALS patients. Similarly, we found that size of
muscle fibers is markedly reduced in transgenic TDP-43
pigs (Fig. 4c, d). Examination of other peripheral tissues
such as heart, liver, stomach, intestines, and kidney
did not reveal any significant difference between non-
transgenic and transgenic TDP-43 pigs. Although we
cannot rule out that the peripheral toxicity of transgenic
TDP-43 also contributes to the severe phenotypes of trans-
genic pigs, the evidence for neurodegeneration in trans-
genic TDP-43 pigs indicates the important role of neuronal
toxicity in transgenic TDP-43 and led us to further explore
the mechanism underlying the neurodegeneration.
Interaction of TDP-43 with PSF in the cytoplasm
TDP-43 is involved in gene transcription and RNA spli-
cing via its interactions with other proteins. To identify
any pig proteins that could interact with TDP-43 and are
involved in TDP-43-mediated toxicity in transgenic pigs,
we generated GST-TDP-43 and used it to pull down pig
brain cortex proteins. The GST pull-down uncovered a
band that is specific to GST-TDP-43 pull-down (Fig. 5a).
Via mass spectrometry, this band was identified as the
splicing factor proline-glutamine rich (SFPQ/PSF) or
PSF, an essential pre-mRNA splicing factor required in
spliceosome formation [32–34]. Western blot analysis
confirmed the interaction of PSF in pig brain with GST-
TDP-43 (Fig. 5b). We also generated His-tagged PSF and
purified this recombined protein from bacteria. In vitro
binding showed that His-PSF could bind endogenous pig
TDP-43 and transgenic hTDP-43 in the pig brain cortex
lysates (Fig. 5c). Like TDP-43, PSF contains N-terminal,
Fig. 1 Generation of transgenic TDP-43 pigs. a The plasmid DNA structure for expressing mutant TDP-43 (M337V) under the human ubiquitin promoter
in transgenic pigs. F2A is a peptide sequence that can self-cleave to separate TDP-43 from EGFP in cells. b The numbers of embryos used and
transgenic TDP-43 pigs produced. c PCR genotype analysis of ear tissues from 15 transgenic TDP-43 pigs. Two non-transgenic pig (Control)
ear tissues served as a control
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RRM1, RRM2 and C-terminal domains. To define the
binding region in TDP-43, we generated GST fusion
proteins containing different TDP-43 fragments (1–251,
1–414, and 264–414 amino acids) and used these GST
fusion proteins to incubate with His-PSF proteins con-
taining different regions (Fig. 5d). The results revealed
that C-terminal PSF (444–707 amino acids) binds GST
fusion protein containing C-terminal (264–414 amino
acids) TDP-43 (Fig. 5e and f).
PSF is found to interact with NeuN to activate neural
cell-specific alternative splicing [35]. We then examined
the effect of transfected TDP-43 on the association of PSF
Fig. 2 Progressive phenotypes of transgenic TDP-43 pigs. a Body weight reduction in different transgenic TDP-43 pigs at different ages. b Body
weight (mean ± SE) of non-transgenic and transgenic TDP-43 pigs at 3, 4, 9 and 10 months of age (n = 5 for non-TG (Control) and n = 5 for
TDP-43 transgenic pigs (TG)). * p < 0.05; ** p < 0.01. c Western blots analysis of ear tissues showing the expression of transgenic TDP-43 pigs
that were monitored for their body weights. d Survival plot showing that expression of mutant TDP-43 caused early death of TDP-43 transgenic (TG) pigs
(n = 12 for non-TG (Control) and n = 27 for TG). e Photographs of representative non-transgenic (Control) and TDP-43 transgenic pig (TG-16, 18, 24) at
9 months of age. f Summary of some transgenic pigs for their genotypes and phenotypes. C: Genotype is non-transgenic with the endogenous
copies of pig TDP-43
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with NeuN. Immunoprecipitation of transfected TDP-43
in mouse N2A cells revealed that mutant TDP-43
(M337V) bound more PSF and NeuN than did wild-type
TDP-43 (Fig. 6a). The in vivo interaction of TDP-43 with
PSF/NeuN in the pig brain lysates was also verified via
immunoprecitation with an antibody to TDP-43 (12892-1-
AP from Proteintech) that selectively precipitated and
detected human TDP-43 but not endogenous pig TDP-43
(Fig. 6b). We also treated the lysates with RNase to
remove RNA before immunopreciptation. Depletion of
RNA by this RNase treatment significantly diminished the
interactions of TDP-43 with FUS, which is a RNA-binding
protein whose interaction with TDP-43 depends on RNA
[6, 36, 37]. There was also a slight decrease in the associ-
ation of TDP-43 with PSF, but not NeuN, compared to
those without RNase treatment (Fig. 6b), suggesting that
the interactions of TDP-43 with its partners are differen-
tially influenced by RNA in cells.
Fig. 3 Expression of transgenic TDP-43 in the pig brain tissues. a Western blot analysis the brain cortex and spinal cord tissues of several transgenic
TDP-43 pigs using antibodies to TDP-43 and flag. C: non-transgenic. b Comparison of the transgenic TDP-43 expression in different brain and peripheral
tissues in TG-11 and TG-18 pigs. Bracket indicates degraded fragments of transgenic TDP-43. CTX, cortex; CB, cerebellum; LSC, lumbar spinal cord; WM,
white matter; BS, brain stem; STR, striatum; HP, hippocampus; SC, spinal cord. Right panel shows quantification of the ratios of endogenous pig TDP-43
to actin in non-transgenic (Control) pig brains and transgenic TDP-43 to actin on western blots (mean ± SE, n = 5 pigs per group). c The brain cortex
from non-transgenic (Control) and TDP-43 transgenic pig (TG-16) pigs was stained with anti-NeuN. Layers of the pig brain cortex were indicated,
showing a reduced thickness of transgenic TDP-43 pig brain cortex compared to the non-transgenic pig brain cortex. Scale bar: 200 μm
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Fig. 4 Expression of mutant TDP-43 in transgenic pigs causes neurodegeneration and muscle atrophy. a CHAT- and NeuN-immunostaining of
the pig spinal cord showing a reduced number of motor neurons in TDP-43 transgenic pigs (TG-16 and 18) at 10–11 months of age. Control:
non-transgenic. Scale bars: 200 μm. b Quantitative analysis of the number (mean ± SE) of NeuN- and CHAT-positive neurons per ventral horn in
the spinal cord sections. Five-eight images obtained with 20x N.A. 0.8 objective per section and 5 sections per group were analyzed. C:
non-transgenic. c Skeletal muscle atrophy in TDP-43(M337V) transgenic pigs. Haematoxylin and eosin-stained cross-sections gastrocnemius
muscles from 10-month-old non-transgenic (Control) and TDP-43(M337V) transgenic (TG-16) pigs. Scale bar: 50 μm. d More than 3 random
fields (corresponding to 200–300 cross-sectioned fibers) were examined for quantification of muscle fibers of different sizes
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Fig. 5 TDP-43 interacts with PSF and NeuN. a Silver-staining of 4-12 % SDS-PAGE gel showing GST-TDP-43 pull-down from pig cortex lysates. GST
served as a control. The indicated band was analyzed by mass spectrometry and found to contain PSF. b Western blotting with anti-PSF verifying
the interaction of GST-TDP-43 and PSF in pig brain cortex lysates. Two GST and GST-TDP-43 pull-down proteins were analyzed. c Purified His-PSF
was incubated with transgenic pig brain cortex lysates, and the bound proteins were subjected to western blot, which shows the in vitro direct
interaction of endogenous pig TDP-43 and transgenic human TDP-43 with His-PSF. Input is 5 % of purified His-PSF, and 40 % of pulldown was
loaded into the SDS gel. d PSF contains N-terminal, RRM1, RRM2, and C-terminal domains. The N-terminal domain is a glycine/proline/arginine
rich domain, the C-terminal and the NOPS regions of PSF were found to bind to TDP-43. TDP-43 contains N-terminal, RRM1, RRM2, and C-terminal
(G-rich) domains. e Purification of His-PSF containing different domains as indicated with the corresponding amino acid positions. f In vitro GST-pull
down identifying that the C-terminal regions containing amino acids 444–707 of PSF bind to C-terminal GST-TDP-43 (amino acids 264–414), but not
N-terminal TDP-43 (amino acids 1–251)
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Mutant TDP-43 causes the cytoplasmic mislocalization of
PSF and NeuN
After verifying the in vivo association of TDP-43 with
PSF and NeuN, we wanted to know whether their sub-
cellular localization is altered in TDP-43 transgenic pig
brain. We performed immunocytochemical studies of
the spinal cord of transgenic TDP-43 pigs and observed
that TDP-43 was concentrated in the nucleus and also
distributed in the cytoplasm (Fig. 7a). Immunostaining
of PSF in the same tissue showed more cytoplasmic
staining of PSF in neuronal cells in the spinal cord of
transgenic TDP-43 pigs (Fig. 7a). To validate whether
cytoplasmic TDP-43 causes more PSF to mislocalize in
the cytoplasm, we performed double immunofluorescent
staining. In those neurons that showed cytoplasmic
transgenic TDP-43, cytoplasmic transgenic PSF was in-
deed present (Fig. 7b). Counting neurons in the spinal
cord of two non-transgenic (78 neurons) and three
TDP-43 pigs (128 neurons) showed that more neurons
(32.3 %) in TDP-43 pig spinal cord displayed a strong
cytoplasmic distribution of PSF than those in non-
transgenic pigs (4.5 %). To provide additional evidence
for this cytoplasmic distribution, we performed western
blot analysis of TDP-43 immunoprecipitation of cytoplas-
mic and nuclear fractions of transgenic TDP-43 pig brain
cortex tissues. Transgenic mutant TDP-43 was precipitated
with anti-flag so its specific precipitation can be verified
by comparing with non-transgenic pig tissues. We also
saw the distribution of mutant TDP-43, PSF, and NeuN
in the cytoplasmic fraction from TDP-43 transgenic pig
brain tissue (Fig. 7c and d). Thus, both immunocyto-
chemical and immunoprecipitation results support the
idea that transgenic mutant TDP-43 in the cytoplasm
caused PSF and NeuN to mislocalize in the cytoplasm
via their interactions.
Mutant TDP-43 affects PSF/NeuN-mediated RNA splicing
The interaction of TDP-43 with PSF/NeuN led us to
focus on alternative splicing of NMHC II-B (myh 10),
nonmuscle myosin heavy chain II-B whose splicing is
regulated by PSF and NeuN [35] and is important for
neuronal function via regulation of NMDA receptor traf-
ficking [38–40]. NMHC II-B is alternatively spliced via
PSF/NeuN to include or exclude a small exon encoding
30 nucleotides, resulting in NMHC II-B +N30 or –N30
isoforms (Fig. 8a). Using RT-PCR analysis, we found that
there was more –N30 isoform exclusion in the brain of
TDP-43 transgenic pig (Fig. 8b). To examine whether
this abnormal splicing affects the expression of NMHC
II-B at the protein level, we performed western blotting
Fig. 6 Interactions of TDP-43 with PSF and NeuN. a Representative western blots showing co-immunoprecipitation of transfected flag-TDP-43
(WT or mutant TDP-43 (M337V)) by anti-flag and endogenous PSF, NeuN in mouse N2A cells. IgG immunoprecipitation served as controls. The
ratios of precipitated to input were obtained from 3 independent experiments and shown beneath the blots. b The in vivo interaction of TDP-43
(M337V) with PSF and NeuN in the non-transgenic (C) pig and transgenic TDP-43 (TG) pig brain. The immunoprecipitation was also pre-treated
with RNase to remove RNA. An antibody to TDP-43 (12892-1-AP from Proteintech) selectively detected human TDP-43, but not endogenous pig
TDP-43. The interaction of FUS with TDP-43, which depends on RNA, served as a control. Quantitative data (ratio of IP/input) are presented
beneath the blots. IP bands indicated by arrows were used for quantification. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with –RNase treatment
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analysis of cytosolic and nuclear fractions of the pig brain
cortex. We were unable to obtain freshly isolated pig brain
tissues for fractionation such that the frozen pig brain tis-
sues may affect the separation of subcellular compartments.
However, by comparing non-transgenic and transgenic
TDP-43 pig brain fractionation samples, we found that
transgenic TDP-43 pig brain showed decreases of NMHC
II-B in the total, nuclear, and cytoplasmic fractions, in-
dicating that mutant TDP-43 reduces the level of NMHC
II-B (Fig. 8c). To confirm that this decrease also occurred
in spinal cord, we performed immunostaining of transgenic
TDP-43 pig spinal cord and observed that the NMHC II-B
staining of motor neurons is much weaker than that in
non-transgenic neurons (Fig. 8d).
Fig. 7 Cytoplasmic mislocalization of PSF and TDP-43 in the spinal cord of transgenic pigs. a TDP-43 and PSF antibody immunocytochemistry of
the spinal cord regions of non-transgenic (Control) pig and TDP-43 transgenic (TG-23) pigs. Arrows indicate the nuclei of neurons. Scale bar:
50 μm. b Immunofluorescent labeling of the spinal cord sections of the TDP-43 pig (TG-23) showing that in motor neurons (arrows) expressing
transgenic TDP-43 (green), cytoplasmic distribution of PSF (red) is also evident. The nuclei were stained with Hoechst. Arrows indicate neurons in
which transgenic TDP-43 is localized in both the nucleus and cytoplasm. Note that the nuclei (arrowheads) of large motor neurons were weakly
labeled by Hoechst. Scale bar: 50 μm. c Flag-TDP-43 immunoprecipitation of the spinal cord sections of the TDP-43 pig revealing that PSF and
NeuN were co-precipitated with cytoplasmic TDP-43 from transgenic pig tissues. C: non-transgenic. Rabbit IgG immunoprecipitation and non-transgenic
pig brain tissues served as a control. d The relative levels (mean ± SE) of proteins (the ratio of IP/Input on the same blot) are presented in the right panel
(n.s.: no significant difference; *p< 0.05; **p< 0.01; ***p< 0.001)
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To prove a causal role of TDP-43 in reducing NMHC
II-B levels, we transfected mutant TDP-43 in PC12 cells
and then examined the half-life of endogenous NMHC
II-B using cycloheximide treatment. The transfection
of TDP-43 promoted the degradation of endogenous
NMHC II-B in PC12 cells (Fig. 9a). Because NMHC
II-B consists of +N30 and –N30 isoform and mutant
TDP-43 promotes the generation of –N30, we wanted
to compare the half-life of +N30 and –N30. Thus, we
generated GFP-NMHC II-B (+N30 and-N30) isoforms
and expressed them in transfected N2A cells, which allows
for high transfection efficiency of this fusion protein. We
found that –N30 is degraded faster than +N30 (Fig. 9b).
Also, the degradation of –N30 is inhibited by the prote-
asome inhibitor MG132, but not the autophagy inhibitor
BFA (Fig. 9c), suggesting its degradation is mediated
by the ubiquitin-proteasome system (UPS). Taken together,
our results suggest that TDP-43 affects PSF/NeuN-me-
diated splicing of NMHC II-B and leads to more –N30
isoform being generated, which is unstable and degraded
quickly by the UPS, resulting in a reduced level of NMHC
II-B.
Cytoplasmic mislocalization of TDP-43 and NMHC II-B
expression in ALS patient brains
We have obtained ALS patient brain tissues that were
found to contain TDP-43 aggregates. Because ALS pa-
tient brains had undergone extensive neurodegeneration,
we had to examine the neurons that were not degener-
ated and remained clear cell body morphology in order
Fig. 8 Mutant TDP-43 causes abnormal splicing of NMHC II-B and promotes NMHC II-B degradation. a Diagram of the mouse NMHC II-B gene
from exon 5 to exon 9. The exons are shown as boxes and the lines between exons are introns. The IDDE sequence is the NeuN binding region,
and the alternative splicing exon N30 is indicated as red box between exon 5 and exon 6. The P5’ and P3’ represent the PCR primers to identify
N30 inclusion (+N30) or exclusion (−N30). b RT-PCR gel result (upper panel) and quantification (lower panel) of the inclusion (+N30) and exclusion
(−N30) of exon N30 in the brain cortex of non-transgenic and transgenic TDP-43 pigs (TG-5, −7, −11, −13, −15, −17, −23, −25). GAPDH served as
a control. Relative +N30 and -N30 isoform levels are shown below each lane and are normalized by the total NMHC II-B gene amount. c Western
blot analysis is unable to distinguish +N30 and –N30 because of their few amino acid differences but shows a decrease of NMHC II-B in homogenates,
cytoplasmic, and nuclear fractions from transgenic TDP-43 pig cortex compared with non-transgenic (C) pig. GAPDH and TFIID are cytoplasmic and
nuclear marker proteins, respectively. The relative levels of NMHC II-B, NeuN, PSF, and TDP-43 in the homogenates (Hom) (ratios of homogenate
proteins to GAPDH) as well as cytosolic (Cyto) (ratios of cytoplasmic proteins to GAPDH) and nuclear (ratios of nuclear proteins to TFIID) fractions are
presented beneath the blot. The data are mean ± SE (n = 3 animals per group). *p < 0.05; **p < 0.01 compared with non-Tg. d Reduced NMHC II-B
immunostaining in the motor neurons in the spinal cord of transgenic TDP-43 (TG) pig compared with non-Tg (Control) pig. Two representative images
are shown. Scale bar: 50 μm
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to assess protein subcellular distribution. We found that
those neurons in the ALS brains show more cytoplasmic
distribution of PSF and NeuN in the cerebellar cortex and
spinal cord than those in the control brains (Fig. 10a). The
cytoplasmic colocalization of NeuN and PSF was not seen
in the control human brain section and requires the
presence of both primary antibodies to NeuN and PSF
(Fig. 10b), indicating the specific colocalization in ALS
patient brains. Counting the percentage of cells containing
cytoplasmic staining of NeuN and PSF also verified that
ALS patient brains displayed more cytoplasmic NeuN and
PSF (Fig. 10c). Because the postmortem human brain tis-
sues were not well-preserved, there was difficulty in using
immuofluorescent staining to analyze these tissues. Des-
pite this, we were also able to find that the ALS patient
brain cortex contained more cytoplasmic TDP-43 and PSF
than the control individual that was not affected by ALS
(Fig. 11a). Immunoprecipitation of TDP-43 from the
cytosolic and nuclear fractions of ALS patient and control
individual brain cortex tissues revealed that more PSF and
NeuN were precipitated by the higher level of cytosolic
TDP-43 in the ALS patient sample than the control sam-
ple (Fig. 11b and c). All these results from ALS patient
samples support the findings from transgenic TDP-43 pig
brains for the cytoplasmic distribution of PSF and its
interaction with mutant TDP-43.
Next, we wanted to see if NMHC II-B level is also de-
creased in ALS patient brains. Using RT-PCR to examine
alternative splicing of NMHC II-B, we found that tissues
from 5 ALS patient cortexes contained more –N30 iso-
forms than Alzheimer’s disease (AD) and control nor-
mal individual brains (Fig. 11d). Western blot analysis
of the cerebellar cortex tissues from five ALS patients
and their controls also validated the decreased levels of
NMHC II-B in the ALS patient brains as compared
with the control normal individual brains (Fig. 11e).
Some AD patient samples show smear by anti-NMHC
II-B staining, perhaps because of tissue degeneration in
AD brains. However, the increased –N30 band in ALS
patient samples (Fig. 11c) and the short half-life of –N30
Fig. 9 Mutant TDP-43 increases the degradation of NMHC II-B. a The half-life of NMHC II-B after cycloheximide (20 ng/ml) treatment of PC12 cells
that were transfected with TDP-43 (M337V). Immunoblots were probed with anti-NMHC II-B for detecting endogenous NMHC II-B, anti-Flag for
the transfected TDP-43, and anti-GAPDH for a loading control protein. Arrow indicates NMHC II-B and the band above 90 kDa is a non-specific
protein reactive to anti-NMHCII-B. Quantification data of % of 0’ time point are presented in the right panel (n = 3). b Fluorescent images of transfected
N2A cells expressing GFP-NMHC II-B (+N30) or (−N30) after cycloheximide treatment. The right panel shows quantitative fluorescent signals of
transfected proteins over time and demonstrates that (−N30) isoform is degraded faster than (+N30). Scale bar: 20 μm. c Western blot (the left
panel) and quantification analysis (the right panel) of transfected GFP-NMHC II-B (−N30) degradation in the N2A cells that were treated with
cycloheximide (20 ng/ml) and MG132 (5 μM) to inhibit the proteasome or BFA (100 μM) to inhibit autophagy
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Fig. 10 (See legend on next page.)
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(See figure on previous page.)
Fig. 10 Cytoplasmic mislocalization of PSF, reduction of NMHC II-B, and abnormal splicing of NMHC II-B in the brains of ALS patients. a Double
immunofluorescent staining of the cortex and spinal cord from the ALS patient and non-ALS individual (control) with antibodies to PSF and
NeuN. Scale bars: cortex: 10 μm. Spinal cord: 50 μm. Note that ALS patient brain shows cytoplasmic distribution of PSF and NeuN. b Immunostaining
of the brain cortex in control and ALS patients with single anti-PSF only revealed PSF immunofluorescent staining. c Quantitative analysis of
the percentage of cells with cytoplasmic PSF and NeuN staining. The staining of the nuclear protein TFIIB served as controls. The data are
mean ± SE by counting 60 to 80 cells per sample (n = 3per group). *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 11 Interactions of TDP-43 with PSF and reduced NMCH II-B in ALS patient brains. a Representative images of cytoplasmic mislocalization of
PSF and TDP-43 in the ALS patient brain. Double immunofluorescent staining of the brain cortex from ALS patient and non-ALS individual with
antibodies to TDP-43 and PSF. Note that ALS patient brain contains cytoplasmic TDP-43 and PSF. Scale bar: 10 μm. b Immunoprecipitation of
TDP-43 in the cortex tissue of ALS patient showing the presence of TDP-43, PSF, and NeuN in the cytoplasmic fraction. CTL is the sample from a
normal individual. Rabbit IgG served as a control immunoprecipitation. Whole: cortex total lysates; Cyto: cytoplasm of cortex lysates; Nucl: nuclear
of cortex lysates; c The ratios (mean ± SE, n = 3) of immunoprecipitate (IP) to input and cytoplasmic or nuclear proteins to total lysates on western
blots are presented. *p < 0.05; **p < 0.01 compared with CTL. d RT-PCR gel result (the upper panel) and quantification of the relative levels
(the lower panel) of +N30 and -N30 isoforms in the brain cortex samples from 3 normal individuals (control), 3 Alzheimer’s disease (AD), and 5
ALS patients. e NMHC II-B western blot analysis of the brain cortex from normal individuals, Alzheimer’s disease (AD) and 5 ALS patients showing
decreased expression of NMCH II-B in ALS patient brains
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(Fig. 9) support the finding that NMHC II-B is decreased
in ALS patient brains.
Since NMHC II-B is important for neuronal intracellular
trafficking of receptors like NMDA receptor [38–40] and
since the lack of NMHC II-B can affect early development
[41] and neurite outgrowth [42], we assumed that overex-
pression of NMHC II-B should diminish TDP-43-mediated
toxicity if TDP-43 reduces NMHC II-B in neuronal cells.
To test this idea, we transfected mutant TDP-43 with
NMHC II-B (+N30) in cultured primary cortical neurons
from mice. Overexpression of mutant TDP-43 could
significantly reduce neurite growth of cultured mouse
cortical neurons, which is largely dependent on intracellular
trafficking of a variety of molecules and receptors. This re-
duced neurite growth could be alleviated by co-transfection
with +N30, but not –N30, NMHC II-B (Fig. 12a). Consist-
ently, by measuring the length of neurites of those mouse
cortical neurons expressing M337V with +N30 or –N30
NMHC II-B, we found that +N30 NMHC II-B mitigated
TDP-43 toxicity on the neuritis outgrowth (Fig. 12b).
However, this protection is partial, indicating that TDP-43
mediates toxicity via multiple pathological pathways.
Nevertheless, the protection seen with overexpressed
NMHC II-B supports the idea that TDP-43 does affect
the expression of NMHC II-B.
Based on the finding that mutant TDP-43 interacts with
PSF, we proposed a model for the effects of cytoplasmic
mislocalization of mutant TDP-43. In this model, patho-
genic TDP-43 is distributed in the cytoplasm. Due to its
association with PSF and NeuN, the cytoplasmic mislocali-
zation of TDP-43 may lead to the increased levels of PSF
and NeuN in the cytoplasm, thereby reducing the nuclear
levels of PSF and NeuN. The reduced PSF/NeuN in the
nucleus can impair the nuclear function of these proteins
and lead to abnormal RNA splicing, such as greater
production of –N30 isoform, which is unstable or be-
comes toxic. The reduced level of NMHC II-B therefore
contributes to the neuropathology caused by mutant
TDP-43 (Fig. 12c).
Discussion
TDP-43 contains a bipartite nuclear localization signal
sequence and a nuclear export signal that allows nuclear-
cytoplasm shuttling [28]. TDP-43 is normally distributed in
the neuronal nucleus but pathogenic TDP-43 mislocalizes
in the cytoplasm and forms ubiquitinated inclusions in the
Fig. 12 Overexpression of NMHC II-B reduces TDP-43-mediated neurite toxicity. a Representative immunofluorescent images of TDP-43 (green),
NMHC II-B (red), and nuclei (blue) in primary neurons from the mouse cortex, which were transfected with mutant TDP-43 (M337V) and NMHC II-B
(+N30) or NMHC II-B (−N30). Note that transfected TDP-43 produced much intense immunostaining signals over the background level in
non-transfected cells. Scale bars: 10 μm. b Quantitative data of neurite length of transfected cells. NMHC II-B (+N30) transfection could promote
neurite outgrowth and also partly rescue the neurite outgrowth defect caused by mutant TDP-43. The data were obtained by counting more than 300
transfected cells per group in 3 independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 compared with TDP-43 transfection alone. GFP: GFP
protein; +N30: NMHC II-B (+N30); −N30: NMHC II-B (−N30); WT-TDP-43: wild type TDP-43; MT-TDP-43: mutant TDP-43 (M337V); MT-N30+:
mutant TDP-43 (M337V) and NMHC II-B (+N30); MT-N30-: mutant TDP-43 (M337V) and NMHC II-B (−N30). c Proposed model of TDP-43 neuronal
toxicity. Because of the interaction of TDP-43 with PSF, the cytoplasmic mislocalization of TDP-43 leads to the cytoplasmic distribution of
PSF and NeuN and reduces the nuclear function of PSF and NeuN on the splicing of NMHC II-B, leading to the exclusion of N30, which
promotes the degradation of NMHC II-B and affects neuronal function
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brains of ALS and FTLD patients [12–14]. The early death,
body weight loss, and motor deficit indicate that transgenic
mutant TDP-43 affects a variety of brain and body func-
tions, which is consistent with the severe toxicity of mutant
TDP-43 in different animals’ models. It has been well docu-
mented that the levels of TDP-43 are critical for neuropath-
ology, as loss or overexpression of wild type TDP-43 can
cause neurotoxicity and phenotypes in animal models [43,
44]. Although western blot analysis of the homogenized pig
brain tissues showed that transgenic TDP-43 is not overex-
pressed as compared to the endogenous pig TDP-43, it
remains to be determined whether transgenic TDP-43
is overexpressed in specific types of neurons. In addition,
since our study did not include transgenic pigs that express
transgenic wild type human TDP-43, we cannot conclude
that the phenotypes in our transgenic pigs are definitively
caused by the mutation in TDP-43, the expression levels of
transgenic TDP-43, or both.
Since transgenic TDP-43 is expressed ubiquitously under
the control of the ubiquitin promoter, it is also possible that
the toxicity of mutant TDP-43 in peripheral tissues contrib-
utes to the severe phenotypes of TDP-43 pigs, which will
require further experiments to investigate. An interesting
finding in our study is that transgenic mutant TDP-43 is
also distributed in the cytoplasm, a phenomenon that is
seen in patient brains. Viral vector expression of TDP-43 in
cynomolgus monkey spinal cord was found to result in
the cytoplasmic distribution of TDP-43 [45]. Thus, large
animals that are much closer to humans may share
species-specific regulatory mechanisms that underlie the
mislocalization of TDP-43 in the neuronal cytoplasm.
However, the expression levels of transgenic TDP-43
could also influence its subcellular distribution, which
needs to be considered when interpreting this cytoplasmic
distribution phenomenon. Although the mechanisms
underlying the cytoplasmic distribution of TDP-43 in
pathogenic conditions remain to be investigated, this
cytoplasmic distribution is likely to occur in the brain
with age or under pathological conditions and is certainly
associated with genetic mutations in the TDP-43 gene
[46–48]. The pathogenic form of TDP-43, which may
be phosphorylated or carry specific conformation that
can confer interactions with other proteins, is able to
mislocalize in the cytoplasm and forms inclusions in
the aged brain. Although mutations in TDP-43 could
promote the formation of the pathogenic TDP-43, it is
possible that protein interactions with pathogenic TDP-
43 in neurons may be different or modulated differently
in small and large animals, which can explain the cyto-
plasmic distribution of TDP-43 in transgenic pig brains.
Thus, species-related differences underscore the im-
portance of using large animal models to uncover some
important pathological changes that may not occur in
small animals.
How cytoplasmic distribution of TDP-43 contributes
to neuropathology remains unknown. The cytoplasmic
mislocalization of TDP-43 is thought to result in the loss
of the nuclear TDP-43 and its sequestration of other
proteins in the cytoplasm, leading to theories of loss and
gain of function caused by TDP-43 [43, 44]. For example,
cytoplasmic mutant TDP-43 was found to impair axonal
transport of mRNA granules [6]. Using transgenic TDP-43
pigs, we found the evidence that the cytoplasmic mutant
TDP-43 can also cause a mislocalization of RNA splicing
factors in the cytoplasm, offering a new explanation for
the role of cytoplasmic pathogenic TDP-43.
Studies of gene expression in TDP-43 transgenic animal
models indicate that mutant TDP-43 affects the splicing
and expression of a large number of genes [5, 7, 15, 49].
However, it is likely the effect of mutant TDP-43 on gene
expression may not be the same in different cell types and
different disease stages. A new finding from our study
is that TDP-43 can interact with the splicing factor
PSF. The binding region was found in the C-terminal
region of TDP-43, consistent with the fact that this C-
terminal region associates with many other heterogeneous
nuclear ribonucleoproteins (hnRNP) family members. The
association of mutations in this C-terminal region with
ALS and FTLD [9, 10] also supports the idea that the
abnormal interactions of TDP-43 with other hnRNPs or
proteins can affect RNA splicing to induce neuropathology.
Also, mutations in TDP-43 can alter its subcellular distribu-
tion and stability [8, 50, 51], leading to the nuclear and
cytoplasmic effects that account for many kinds of ab-
normal gene expression and RNA splicing.
In TDP-43 transgenic pig brains, we saw diffuse stain-
ing of TDP-43 in the cytoplasm without clear aggregates.
The formation of cytoplasmic aggregates may be age-
dependent or may only occur in old pig brains. The
lack of obvious cytoplasmic TDP-43 aggregates sup-
ports the idea that soluble TDP-43 is toxic in our
TDP-43 transgenic pigs. In fact, this idea has been
suggested by the earlier finding that deleting the NLS
in mutant TDP-43 could cause the cytoplasmic distri-
bution of mutant TDP-43 and severe phenotypes in
transgenic mice without aggregates [52]. Also, aber-
rant RNA splicing was recently found to occur with-
out aggregation and loss of nuclear TDP-43 [53]. This
idea is also supported by the interactions of soluble
TDP-43 with PSF/NeuN and abnormal splicing of
MNHC II-B in transgenic pig and ALS patient brains.
The expression of MNHC II-B is critical for neuronal
development [38–40]. Decreased levels of MNHC II-B
and its point mutations are found to cause neuronal
toxicity and phenotypes in mice and humans [53, 54],
making MNHC II-B a good candidate for investigating
how TDP-43 mediates neuronal function via affecting
NMHC II-B gene slicing and expression.
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According to our proposed model, the mislocalization
of TDP-43 in the cytoplasm and its interactions with
PSF/NeuN may contribute to the cytoplasmic distribu-
tion of PSF and NeuN, thereby reducing their effect on
RNA splicing in the nucleus. It is possible that the inter-
action of mutant TDP-43 with PSF/NeuN in the nucleus
can impact the function of PSF/NeuN, as the reduced
neurite outgrowth of transfected cells showing both
cytoplasmic and nuclear distribution of mutant TDP-43
can be alleviated by NMHC II-B. However, TDP-43 is
known to interact with a large number of proteins. The
contributions of the interactions of TDP-43 with its
partners to ALS pathology may depend on cell types,
subcellular regions, and species-related factors, which
could confer differential posttranslational modifications
to modify these interactions.
Conclusions
Using nuclear transfer technology, we established trans-
genic pigs expressing mutant TDP-43. Like other trans-
genic TDP-43 animal models, transgenic TDP-43 pigs
show severe neurological phenotypes, supporting a toxic
gain of function of mutant TDP-43 in large mammalian
animals. We also found that mutant TDP-43 is distributed
in the cytoplasm in the transgenic pig brain, a phenomenon
that is seen in patient brains. By focusing on the TDP-43-
PSF interaction and its related RNA splicing function, we
provide new evidence for species-dependent cytoplasmic
distribution of mutant TDP-43 and a new insight for how
the cytoplasmic accumulation of mutant TDP-43 can con-
tribute to abnormal gene expression. These findings should
also have implications for identifying other pathological
pathways and interacting proteins involved in ALS and
FTLD and help uncover therapeutic targets, as well.
Methods
Plasmids and antibodies
pBudCE4.1-PSF was obtained from Dr. V.M. Kalscheuer’s
lab [55]. pEGFP-NMHC II-B (−N30) was obtained from
Addgene, and pEGFP-NMHC II-B (+N30) was constructed
by inserting +N30 sequences into pEGFP-NMHC II-B
(−N30) using primers and PCR. The shRNA of NMHC
II-B (TL711338A, TL711338B, TL711338C and TL711338D)
were obtained from Origene. Other constructs of GST-TDP-
43(1-414-M337V), GST-TDP-43(1–251), GST-TDP-43(264–
414), GST-TDP-43(264-414-M337V), His-PSF(1–707),
His-PSF(297–369), His-PSF(444–495), His-PSF (496–707),
His-PSF(444–707), pRK-TDP-43(M337V), pRK-C-TDP-43,
pRK-C-TDP-43(M337V), pEGFP-TDP-43(M337V) and
pEGFP-NMHC II-B (+N30) were generated using the
above plasmids or using PCR primers to amplify the first
strand cDNAs of human brain tissues and constructed
in the pRK5 or pCDNA3 vector. For antibodies, rabbit
polyclonal antibody to TDP-43 was raised against GST-
TDP-43 at the Institute of Genetics and Developmental
Biology in Beijing and was used for immunoprecipita-
tion. Antibodies to PSF (Ab38148), P84 (5E10), Flag
(Ab21536) and NMHC II-B [3H2] (ab684) were obtained
from Abcam. Other antibodies purchased include: NeuN
(mAb377) from Millipore; TDP-43 (12892-1-AP) from
Proteintech; TDP-43 (G400) from Cell Signaling; TDP-43
(M01) from Abnova; GFP (GT859) and FUS (GTX63610)
from GeneTex; GAPDH (G-9), beta-actin (C-4), Adpatin B
(N-19), hnRNPK (D-6), TFIID (N-12), GST (A-6) and His
(H-15) from Santa Cruz Biotechnology.
Transgenic pigs
Animal use followed the NIH Guide for the Care and
Use of Laboratory Animals. The animal use protocol
was approved by the Institutional Animal Care and Use
Committees (IACUC) at Guangzhou Institute of Biomedi-
cine and Health (GIBH), Chinese Academy of Sciences.
TDP-43 (M337V) cDNA [56] was tagged with the flag
epitope at its N-terminal region and fused with EGFP
via F2A, a peptide sequence that is self-cleaved to separate
TDP-43 from EGFP in cells. EGFP served as a reporter for
selecting TDP-43 transfected cells. The cDNA was inserted
into the vector (pCAG-Neo) containing the neo-resistant
gene and the CAG promoter were replaced with the human
ubiquitin (hUPC) promoter. The constructed TDP-43
vector (phUBC-TDP-43(M337V)-F2A-GFP) was then
transfected via electroporation (Gene PulserXcell, Bio-
Rad, Hercules, CA, USA) into primary pig fetal fibroblasts
isolated from a 35-day fetus of a female Tibet miniature
pig. The fetal fibroblasts were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, HyClone, Logan,
UT, USA) supplemented with 15 % fetal bovine serum
(FBS, HyClone, Logan, UT, USA) and 1 % (v:v) penicillin/
streptomycin (10,000 U/ml penicillin, 10,000 μg/ml strepto-
mycin; GIBCO-BRL, Grand Island, NY, USA) at 39 °C in
an incubator with 5 % CO2. After 48 h, 500 μg/ml G418
(Merck, Darmstadt, Germany) was added to the medium
to select transfected cell colonies, and the plates were incu-
bated in media containing G418 for approximately 10 d.
The surviving cell colonies were selected and propagated in
a fresh 48-well plate. Colonies that proliferated well were
then expanded and screened for the expression of TDP-43.
The ovaries of pigs were collected from long white
pigs at a local slaughterhouse. The cumulus-oocyte com-
plexes were isolated and cultured as described previously
[26, 27]. After 42–44 h of culture, oocytes were sepa-
rated from cumulus cells by vigorous vortex for 4 min in
TL-Hepes supplemented with 0.1 % polyvinyl alcohol
(P8136; Sigma) and 0.1 % hyaluronidase (H3506; Sigma).
Denuded mature oocytes were enucleated and injected
with a single donor cell into the perivitelline space of the
oocyte in contact with the oocyte membrane. Fusion and
activation were induced simultaneously with 2 successive
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DC pulses of 1.1 kV/cm for 30 ms using an Electro Cell
Manipulator 200 (Genetronics, San Diego, CA, USA).
Reconstructed embryos (50–100) were transferred to
500 μl of culture medium covered with mineral oil in
a four-well multi dish and cultured in 5 % CO2 for
18–22 h at 39 °C. The embryos were then surgically
transferred into the oviduct of a surrogate female on
the first day of standing estrus. Pregnancy status was
monitored using an ultrasound scanner between days
30–35 post-transplantation. Transgenic piglets were identi-
fied by PCR using primers (forward primer: 5’-TTGAACT
ATGCGCTCGGGGTTG-3’ and reverse primer: 5’-GTTC
GGTTGTTTTCCATGGGAGAC-3’) and western blot ana-
lysis with anti-TDP-43 antibodies.
Animal behavioral studies
The movement capabilities of transgenic pigs were tested
by treadmill running as described in our recent study [27].
A suitable cage was placed onto the treadmill to keep the
pig and make it run on the conveyer belt. Pigs were
trained 3 times for running on treadmill and then were
tested from the age of 3 months. The speed of treadmill
was kept at 3.0 km/h for 1 min when the pig ran on it.
Non-transgenic littermates or age- and body weight-
matched non-transgenic pigs were used as controls.
Due to their severe phenotypes, TDP-43 transgenic pigs
often died in the course of training or formal test of
their motor function such that we did not test all TDP-43
transgenic pigs.
Human tissue acquisition
Human cortex and spinal cord tissues were obtained and
archived via an institutional review board and Health
Insurance Portability and Accountability Act-compliant
process at neuropathology/histochemistry core of Emory
University. Autopsies were performed following death
with post-mortem interval of 6–13 h. The spinal cord
and cortex tissues were obtained from the postmortem
brains of ALS patients (04–56, E11-75, E09-35, E-86,
and E-81) who died at 67–74 years of age and were
confirmed to have TDP-43 aggregates via post-mortem
histologic analysis. Non-ALS tissues were obtained from
neurologically unaffected patients (E08-137, E06-45, and
E06-114) and Alzheimer’s disease patients (E11-97, E11-
139, and E12-110) who died at 53–92 years of age. For im-
munofluorescence studies, tissues were fixed in formalin
and embedded by paraffin, sectioned, and stored at room
temperature (16-25 °C). For Co-IP and RT-PCR analysis,
tissue segments stored at −80 °C were used.
GST pulldown assays
GST-TDP-43 recombinant fusion proteins were produced
in bacteria (BL21) and purified with glutathione-sepharose
beads (Sigma). Pig cortex tissues (0.1 g/ml) in NP-40 lysis
buffer (50 mM Tris pH7.4, 50 mM NaCl, 0.1 % Triton
X-100, 1 % NP40) were homogenized using a Teflon
homogenizer for 30 strokes. The lysates were added
with protease inhibitor cocktail (Sigma, P8340) plus
proteasome inhibitor and kept on ice for 30 min. Lysates
were sonicated for 10 s and centrifuged at 1000 × g for
2 min. The supernatants (5 μg/μl protein) were pre-
cleaned by incubating with 100 μg GST protein and 30 μL
glutathione-sepharose beads for 4 h at 4 °C and then sub-
jected to GST-TDP-43 pull-down assay. Analysis of the
GST-TDP-43 pull down bands was performed by AB
SCIEX TripleTOF® 5600 system at Institute of Genetics
and Developmental Biology in Beijing.
Co-immunoprecipitation and western blot
Cultured cells or brain tissues were homogenized in NP-
40,1 × PBS or RIPA buffer with 1× protease inhibitor as
previously described [57]. For immunoprecipitation, the
lysates were centrifuged at 800 × g for 5 min, and super-
natants were incubated with antibody and Protein A
beads (Sigma-Aldrich) at 4 °C overnight, followed by wash-
ing with lysis buffer 4 times. The samples were subjected
to 4-12 % SDS-PAGE (Invitrogen) and detected with
SuperSignal West Dura Extended Duration Substrate
(Thermo). For RNase treatment, pig cortex lysates were
incubated with 200 μg/ml RNase A for 30 min at 25 °C
before immunoprecipitation.
Subcellular fractionations
The cytosolic fraction was obtained by centrifuging the
brain lysates at a high speed 15000 × g for 15 min, the
supernatant was used as cytoplasmic for Western Blot
and Co-Immunoprecipitation. For nuclear fractionation,
we added 1000 μl of NP-40 buffer to 0.1 g pig brain cor-
tex tissue on ice for 10 min. The tissues were then ho-
mogenized with a glass homogenizer for 30 strokes and
sonicated of 15 s. The lysates were centrifuged at 4 °C at
800 × g for 10 min. The pellets were re-suspended in
374 μl of buffer (5 mM HEPES, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 26 % glycerol (v/v), pH 7.9) with
26 μl of 4.6 M NaCl to give the final concentration at
300 mM NaCl and then homogenized with 20 full strokes
in Teflon homogenizer on ice and sonicated for 10 s.
The homogenized samples were kept on ice for 20 min
and then centrifuged at 24,000 × g for 20 min at 4 °C.
The supernatant was used for western blotting or
Immunoprecipitation.
Cell cultures
PC12 cells stably expressing flag-TDP-43-EGFP were de-
scribed in our recent study [56]. HEK293T and SK-N-SH
cells were purchased from the ATCC and cultured ac-
cording to the guidelines recommended by the ATCC.
All cells were maintained at 37 °C with 5 % CO2. PC12
Wang et al. Molecular Neurodegeneration  (2015) 10:42 Page 17 of 20
cells were maintained in DMEM/F12 medium with 5 %
fetal bovine serum and 10 % horse serum, 100 U/ml
penicillin at 37 °C in an atmosphere of 5 % CO2 and
95 % humidity. NGF was used at 100 ng/ml (N6009,
Sigma) to induce neurite extension for the PC12 cells.
Culture of primary neurons from mouse brain cortex
was performed as described previously [57]. Briefly, cortical
neurons were isolated from the cortex of postnatal day 1
mice. Dissected tissue was treated with 0.0625 mg/ml
trypsin and 0.0625 mg/ml DNase (Life Technology) in
1 × HBSS buffer without calcium and magnesium for
10 min at 37 °C, followed by triturating with a 1-ml
pipette tip for 20 times. Cells were then washed once
with the tissue culture medium and spun down at 1500 g
for 3 min. Cells were placed on top of a layer of astrocytes
and grown initially in a 50 % glial-conditioned medium
[DMEM containing 0.25 % glucose, 2 mM glutamate,
10 % FCS, 500 nm insulin, 1 × vitamin mixture (M6895;
Sigma), and 1 % antibiotic–antimycotic (Invitrogen)]. The
cells were then cultured in neurobasal/B27 medium.
Immunofluorescence, immunohistochemistry, and
quantification
Sections from human or pig brains were fixed in 4 %
paraformaldehyde/1 × PBS, embedded in paraffin or Tis-
sue ® Tek O.C.T compound (SAKURA), and sectioned to
10 or 40 μm slices. The paraffin embedded sections were
deparaffinized with xylene and sequential ethanol (70 %,
80 %, 100 % X 2 times) and rehydrated with water. Rehy-
drated slices were heat-treated for antigen retrieval in
citrate buffer. The treated slices were then stained by
antibodies to TDP-43, NeuN, and PSF and detected
using DAB staining. Images of micrographs were taken
using a Zeiss microscope (Axiovert 200 MOT).
To quantify neurons expressing transgenic TDP-43 in
transgenic pig brains and ALS patient brains, we used
5–8 images obtained with 20 × N.A. 0.8 objective per
section and 5 sections per group (n = 3-5 samples per
group). To quantify cultured cells, we examined more
than total 300 cells per group in at least three independ-
ent experiments. To measure the lengths of neurites of
cultured neurons, imaged cells were selected at random,
and all visible processes of selected neurons were im-
aged. The transfected neurons whose neurites could be
clearly identified were selected to measure the lengths of
their neurites using a fluorescent microscope of ZEISS
Axiovrert 200 M microscope. The images were analyzed
by measuring the longest branch of each neurite and the
relative length was quantified as pixel using NeuronJ
plugin image software, which is used for quantification
of elongated structures.
For analyzing histological changes in the muscle sec-
tions, a minimum of 3 random fields (corresponding to
200–300 cross-sectioned fibers) were photo micrographed
for gastrocnemius muscle of non-transgenic and TDP-43
transgenic pigs; all type fibers were analyzed for their size
using Scion Image software (v. alpha 4.0.3.2, Scion, Fred-
erick, MD).
Statistical analysis
For statistical analysis, data were obtained from three or
more independent experiments. Statistical analysis was
performed using Microsoft Excel and Student’s t-test
(two tailed) for comparing two different groups. A value
of p < 0.05 or p < 0.01 was indicated with one asterisk (*)
or two asterisk (**), which represent statistically significant.
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